Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Pentamethylchromanol** (PMCol, APC-100) is a small molecule related to vitamin E, composed of a chromanol ring lacking the lipophilic phytyl tail, imparting higher water solubility. It functions as an androgen receptor antagonist and exhibits chemopreventive, antineoplastic, and antioxidant activities. PMCol was studied as an oral agent for the prevention and treatment of androgen-dependent cancers, notably prostate cancer. Its mechanism includes androgen receptor antagonism evidenced in LNCaP prostate carcinoma cells, with antioxidant protection of erythrocytes from free radical-induced hemolysis. Its metabolism varies across species. PMCol is distinguished by water solubility and purported advantages over vitamin E as a chemopreventive agent[1][3][11][12][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentamethylchromanol.